Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ALDH1A2 | O94788 | 2/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.33 |
| ▸ | ALDH1B1 | P30837 | 2/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2105303 | 0.86 | CTRC (0.35) | ALDH1A1ALDH1A2ALDH2ALDH1B1ALDH1A3 | |
| SCHEMBL712681 | 0.85 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL102100 | 0.80 | — | — | |
| SCHEMBL10776128 | 0.79 | — | — | |
| SCHEMBL16020517 | 0.78 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL9963865 | 0.76 | DAO (0.32) | — | |
| SCHEMBL21263178 | 0.76 | — | — | |
| SCHEMBL20842416 | 0.76 | — | — | |
| SCHEMBL950801 | 0.75 | — | — | |
| SCHEMBL6612500 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125408-A1 | (5-propyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate for teating bacterial infections such as bronchitis, sinusitis, otitis media, brain abscess, pneumonia etc; oral bioavailability | PFIZER INC | 2008-05-29 | — | — | US | claimed |
| WO-2008059367-A1 | PENEM PRODRUGS | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | claimed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023184498-A1 | SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK, AND ELECTRIC APPARATUS | 宁德时代新能源科技股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023184490-A1 | SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK AND ELECTRIC DEVICE | 宁德时代新能源科技股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11742523-B2 | Electrolyte solutions | ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023108174-A1 | ANALOGS OF 6-METHOXY- N, N-DIMETHYLTRYPTAMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4097789-A1 | ELECTROLYTE SOLUTIONS | Ascend Performance Materials Operations LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3450423-B1 | BENZYL PHENYL ETHER DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF | INST MATERIA MEDICA CAMS (CN) | 2022-06-15 | — | — | EP | disclosed |
| US-20080125408-A1 | (5-propyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate for teating bacterial infections such as bronchitis, sinusitis, otitis media, brain abscess, pneumonia etc; oral bioavailability | PFIZER INC | 2008-05-29 | — | — | US | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20060229236-A1 | Cyclic tetrapeptide compound and use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1458746-A2 | CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004072047-A1 | INDOLES, BENZIMIDAZOLES OR NAPHHIMIDAZOLES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-26 | — | — | WO | disclosed |
| WO-2003057722-A2 | CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
| US-4717767-A | ANTIBIOTICS | TOYAMA CHEMICAL CO., LTD. (JP) | 1988-01-05 | — | — | US | disclosed |
| US-4698352-A | 4-oxo-1,4-dihydronicotinic acid derivatives, salts thereof, and antibacterial agents containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-10-06 | — | — | US | disclosed |
| US-4618606-A | Antibiotic 7-(thiazolyl)-3-(pyrazinylmethyl) or (pyridazinylmethyl) cephalosporins | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | ALDH1A1 1784/4885ALDH1A2 1736/4885ALDH2 440/4885 |
| US-20060229236-A1 | Cyclic tetrapeptide compound and use thereof | NGLY1, CRH, NPY1R | ALDH1A1 4779/4885ALDH1A2 4783/4885ALDH2 4848/4885 |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | ALDH1A1 1392/4885ALDH1A2 1051/4885ALDH2 522/4885 |
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | ALDH1A1 4695/4885ALDH1A2 4770/4885ALDH2 3903/4885 |
| US-20080125408-A1 | (5-propyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate for teating bacterial infections such as bronchitis, sinusitis, otitis media, brain abscess, pneumonia etc; oral bioavailability | SULT1E1, OXER1, MALT1 | ALDH1A1 727/4885ALDH1A2 2850/4885ALDH2 3378/4885 |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | ALDH1A1 3872/4885ALDH1A2 4356/4885ALDH2 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.